Scinai Immunotherapeutics Ltd. Publishes Peer-Reviewed Data on PC111's Potential as Disease Modifier
TL;DR
Scinai Immunotherapeutics' PC111 offers a competitive edge by providing a non-immunosuppressive treatment for pemphigus and SJS/TEN, potentially transforming care for these conditions and benefiting shareholders.
PC111, a human anti-Fas Ligand monoclonal antibody, works by targeting soluble Fas Ligand to prevent blister formation in pemphigus, as confirmed in a peer-reviewed study.
Scinai's PC111 could significantly improve lives by offering a new treatment option for pemphigus and SJS/TEN, conditions with high unmet medical needs.
Discover how Scinai's PC111, a first-in-class antibody, is pioneering a novel approach to treat severe dermatological conditions without suppressing the immune system.
Found this article helpful?
Share it with your network and spread the knowledge!
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company specializing in inflammation and immunology biological products, has announced the publication of a peer-reviewed article in the Journal of Dermatological Treatment. The article confirms the disease-modifying potential of PC111, a first-in-class human anti-Fas Ligand monoclonal antibody. This development marks a significant step forward in the treatment of pemphigus and Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), conditions with high unmet medical needs.
The study detailed in the article demonstrates PC111's ability to prevent blister formation in humanized models of pemphigus by targeting soluble Fas Ligand. This approach is differentiated by its non-immunosuppressive mechanism, offering a promising alternative to current treatments that often compromise the immune system. Additionally, the data suggests PC111's potential applicability in treating SJS/TEN, a life-threatening dermatological condition, further broadening its therapeutic scope.
Amir Reichman, CEO of Scinai Immunotherapeutics, emphasized the importance of these findings, stating that they reinforce PC111's potential to transform treatment paradigms for these severe conditions. The publication not only underscores the scientific validity of PC111's mechanism but also highlights its potential to deliver significant value to patients and shareholders alike.
For those interested in delving deeper into the findings, the full press release can be accessed here. This publication represents a pivotal moment in Scinai Immunotherapeutics' mission to address critical gaps in the treatment of inflammation and immunology-related diseases, paving the way for innovative solutions that could improve patient outcomes worldwide.
Curated from InvestorBrandNetwork (IBN)
